RT Journal Article
SR Electronic
T1 Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.02.20029975
DO 10.1101/2020.03.02.20029975
A1 Yang, Yang
A1 Shen, Chenguang
A1 Li, Jinxiu
A1 Yuan, Jing
A1 Yang, Minghui
A1 Wang, Fuxiang
A1 Li, Guobao
A1 Li, Yanjie
A1 Xing, Li
A1 Peng, Ling
A1 Wei, Jinli
A1 Cao, Mengli
A1 Zheng, Haixia
A1 Wu, Weibo
A1 Zou, Rongrong
A1 Li, Delin
A1 Xu, Zhixiang
A1 Wang, Haiyan
A1 Zhang, Mingxia
A1 Zhang, Zheng
A1 Liu, Lei
A1 Liu, Yingxia
YR 2020
UL http://medrxiv.org/content/early/2020/03/06/2020.03.02.20029975.abstract
AB The outbreak of Coronavirus Disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, December 2019, and continuously poses a serious threat to public health. Our previous study has shown that cytokine storm occurred during SARS-CoV-2 infection, while the detailed role of cytokines in the disease severity and progression remained unclear due to the limited case number. In this study, we examined 48 cytokines in the plasma samples from 53 COVID-19 cases, among whom 34 were severe cases, and the others moderate. Results showed that 14 cytokines were significantly elevated upon admission in COVID-19 cases. Moreover, IP-10, MCP-3, and IL-1ra were significantly higher in severe cases, and highly associated with the PaO2/FaO2 and Murray score. Furthermore, the three cytokines were independent predictors for the progression of COVID-19, and the combination of IP-10, MCP-3 and IL-1ra showed the biggest area under the curve (AUC) of the receiver-operating characteristics (ROC) calculations. Serial detection of IP-10, MCP-3 and IL-1ra in 14 severe cases showed that the continuous high levels of these cytokines were associated with disease deterioration and fatal outcome. In conclusion, we report biomarkers that closely associated with disease severity and outcome of COVID-19. These findings add to our understanding of the immunopathologic mechanisms of SARS-CoV-2 infection, providing novel therapeutic targets and strategy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Natural Science Foundation of China (Grant 81802004) and the National Science and Technology Major Project (Grants 2018ZX10711001, 2017ZX10204401 and 2017ZX10103011), Sanming Project of Medicine in Shenzhen (SZSM201412003, SZSM201512005).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or used during the study have been presented in the submitted article.